Asgard Therapeutics Revenue and Competitors

Lund, se

Location

$39M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Asgard Therapeutics's estimated annual revenue is currently $5M per year.(i)
  • Asgard Therapeutics's estimated revenue per employee is $155,000
  • Asgard Therapeutics's total funding is $39M.

Employee Data

  • Asgard Therapeutics has 32 Employees.(i)
  • Asgard Therapeutics grew their employee count by 23% last year.

Asgard Therapeutics's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
Co-founder and Head ResearchReveal Email/Phone
3
Co-founder and Head InnovationReveal Email/Phone
4
Head FinanceReveal Email/Phone
5
Senior Director Translational ScienceReveal Email/Phone
6
Senior Scientist Pipeline DevelopmentReveal Email/Phone
7
Associate ScientistReveal Email/Phone
8
Senior Scientist Gene therapyReveal Email/Phone
9
Associate scientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.8M7617%N/AN/A
#2
$12.1M7824%N/AN/A
#3
$5M3223%$39.4MN/A
#4
$2.3M1515%N/AN/A
#5
$2M130%N/AN/A
#6
$2.5M1633%$6.7MN/A
#7
$3.1M2018%$12.3MN/A
Add Company

What Is Asgard Therapeutics?

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient.

keywords:N/A

$39M

Total Funding

32

Number of Employees

$5M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.6M32N/AN/A
#2
$3.3M3223%N/A
#3
$3.7M32-6%N/A
#4
$5.3M34-35%N/A
#5
$4.4M3448%N/A